- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01463293
B. Lactis HN019 for Functional Constipation (CTT)
June 26, 2014 updated by: Fonterra Research Centre
Effects of 4-week Bifidobacterium Lactis HN019 Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This prospective, double-blind, randomized, placebo-controlled clinical trial will investigate the effects of 4-week B. lactis HN019 supplementation on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
Participants who meet all study entry criteria will enter a 2-week run-in period.
Following successful completion of the run-in period, subjects will be randomized to 4-week supplementation with B. lactis HN019 (10 billion cfu), B. lactis HN019 (1 billion cfu), or placebo.
The primary outcome of whole gut transit time will be evaluated with abdominal x-rays on days 0 and 28.
Secondary outcomes include IBS-specific questionnaires (administered on days 0 and 28); abdominal pain severity, bowel movement frequency, stool consistency, and adverse events (evaluated daily throughout the study); and overall product satisfaction (evaluated at day 28).
Physical activity questionnaires and 24-hour food recalls will be completed periodically during the trial.
Study Type
Interventional
Enrollment (Actual)
224
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- Arrowhead Family Health Center
-
-
California
-
Encinitas, California, United States, 92024
- Diagnamics, Inc.
-
Garden Grove, California, United States, 92840
- Digestive & Liver Disease Specialists
-
Northridge, California, United States, 91325
- Staywell Research
-
San Francisco, California, United States, 94109
- Sprim ALS
-
Westlake Village, California, United States, 91361
- Westlake Medical Research
-
-
Texas
-
Carrollton, Texas, United States, 75010
- Research Across America
-
Dallas, Texas, United States, 77054
- Research Across America
-
Houston, Texas, United States, 77025
- Discovery Clinical Trials South Main
-
Katy, Texas, United States, 77450
- Research Across America
-
Plano, Texas, United States, 75024
- Village Health Partners
-
Plano, Texas, United States, 75093
- North Texas Family Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 to 70 years
- Body mass index between 18.5 and 34.9 kg/m2
- Self-reported unsatisfactory defecation due to infrequent stools and/or difficult stool passage, which includes at least one of the following: symptoms of straining, difficulty expelling stool, a sense of incomplete evacuation, hard or lumpy stools, prolonged time to stool, or a need for manual maneuvers to pass stool.
- Estimated stool consistency < 4.0 on BSSF (self-reported at screening) within the past month prior to enrollment.
- Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects
- Consent to the study and willing to comply with study product and methods
Exclusion Criteria:
- Major gastrointestinal complication (e.g. Crohn's disease, ulcer)
- Prior abdominal surgery that, in the opinion of the investigator, may present a risk for the subject or confound study results
- Clinically significant underlying systemic illness that may preclude the subject's ability to complete the trial or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness)
- Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening and throughout the trial other than the provided study products
- Non-laxative constipation medication use within 2 weeks of screening, laxative use within 48 hours of screening (rescue medication allowed for intolerable symptoms during study)
- Daily use of anticholinergic agents, opioid analgesics, calcium supplements, calcium-channel blockers, and NSAIDs
- Anticipated major dietary or exercise changes during the study
- Systemic steroid use
- Eating disorder
- Contraindication to dairy products (e.g., intolerance to lactose or any substance in the study product)
- History of alcohol, drug, or medication abuse
- Pregnant or lactating female, or pregnancy planned during study period
- Participation in another study with any investigational product within 30 days of screening
- Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo capsule
|
Capsule containing no probiotic once a day
|
Experimental: High-dose probiotic
Capsule containing 10 billion cfu B. lactis HN019
|
Capsule containing 10 billion cfu B. lactis HN019 once a day
Capsule containing 1 billion cfu B. lactis HN019 once a day
|
Experimental: Low dose probiotic
Capsule containing 1 billion cfu B. lactis HN019
|
Capsule containing 10 billion cfu B. lactis HN019 once a day
Capsule containing 1 billion cfu B. lactis HN019 once a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whole Gut Transit Time
Time Frame: 4 weeks
|
The primary endpoint of this clinical trial is whole gut transit time, which will be assessed using abdominal x-rays on days 0 and 28
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Assessment of Constipation Symptoms (PAC-SYM)
Time Frame: 4 weeks
|
The PAC-SYM tool asks 12 questions on the symptoms of constipation.
Subjects will complete the PAC-SYM at days 0 and 28.
|
4 weeks
|
Patient Assessment of Constipation QoL (PAC-QoL)
Time Frame: 4 weeks
|
The PAC-QoL is a 28-question survey that asks questions on their quality of life.
|
4 weeks
|
Bowel Function Index
Time Frame: 4 weeks
|
The Bowel Function Index is a 3-question tool that asks subjects if they have experienced adequate relief of constipation symptoms over the past week.
The Bowel Function Index will be completed at days 0 and 28.
|
4 weeks
|
Adequate Relief of Constipation (Yes/no)
Time Frame: 4 weeks
|
Adequate relief of constipation (yes/no) This (yes/no) questionnaire will be completed at days 0 and 28.
|
4 weeks
|
Bowel Movement Frequency
Time Frame: 4 weeks
|
Subjects will record the number of defecations per day in a diary.
|
4 weeks
|
Stool Consistency
Time Frame: 4 weeks
|
Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form
|
4 weeks
|
Overall Product Satisfaction
Time Frame: 4 weeks
|
At the end of the supplementation period, subjects will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale
|
4 weeks
|
Adverse Event Frequency
Time Frame: 4 weeks
|
All adverse events, regardless of relationship with investigational product, will be reported during the 4-week follow-up period.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Hardi, MD, Capital Digestive Care, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
May 1, 2013
Study Registration Dates
First Submitted
October 28, 2011
First Submitted That Met QC Criteria
October 31, 2011
First Posted (Estimate)
November 1, 2011
Study Record Updates
Last Update Posted (Estimate)
July 24, 2014
Last Update Submitted That Met QC Criteria
June 26, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-SUS-02-FON-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on B. lactis HN019
-
Children's Hospital of Fudan UniversityRecruitingPrader-Willi SyndromeChina
-
University of Campinas, BrazilCompleted
-
Danisco Sweeteners OyEurofins OptimedCompletedConstipation | Gastrointestinal DisorderFrance
-
Fonterra Research CentreSprim Advanced Life Sciences; DaniscoUnknown
-
Fonterra Research CentreSprim Advanced Life Sciences; DaniscoCompletedGastrointestinal Symptoms
-
University of Illinois at Urbana-ChampaignNational Honey BoardCompletedGastrointestinal Dysfunction | Physiological Stress | Cognition - OtherUnited States
-
University of FloridaLallemand Health SolutionsCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingProbiotics | Non-Alcoholic Fatty Liver Disease | Microbiome | Gut Microbiome | Fecal Microbiota Transplantation | Intestinal Microbiome | FMT | Non Alcoholic Steatohepatitis | PrebioticsNetherlands
-
University of Sao PauloCompletedOral Lichen PlanusBrazil
-
University of Illinois at Urbana-ChampaignNational Honey BoardCompletedGastrointestinal Dysfunction | Physiological Stress | Cognition - OtherUnited States